We’re delighted to add our latest Educational Series on the management of stage II/III oesophageal, gastro-oesophageal junction and gastric cancer.
The review covers epidemiology, staging, management of stage II/III disease, treatment options, a focus on adjuvant nivolumab following chemoradiation therapy, and ongoing phase 3 trials with immunotherapy as adjunct therapy. It also includes guiding commentary from Associate Professor Louise Nott and Dr David Liu.
Please login below to download this issue (PDF)